Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Pascal Soriot

- PMLiVE

EMA backs drugs from Novo, Otsuka, AZ, Janssen, GSK

Nine new branded medicines recommended for use in Europe

- PMLiVE

FDA to review AZ’s fish oil drug Epanova

Hypertriglyceridaemia treatment acquired as part of Omthera takeover

- PMLiVE

AZ licenses Merck ovarian cancer drug

Pays $50m upfront for MK-1775

- PMLiVE

AZ sponsors heart attack risk app

GRACE 2.0 app aims to help HCPs decide on the most appropriate treatments

- PMLiVE

Rigel plans job cuts in R&D restructure

Follows failure of fostamatinib disodium in rheumatoid arthritis trial

- PMLiVE

AZ’s olaparib enters phase III for ovarian cancer

Development of the drug had previously been halted in 2011

- PMLiVE

AZ launches breast cancer video portal

Pharma company partners with oncology publisher for new HCP resource

- PMLiVE

AZ adds to pipeline again with Amplimmune buy

Pharma company pays $500m via its MedImmune subsidiary for the small US biotech

- PMLiVE

AZ inks $815m deal for FibroGen anaemia drug

Deal comes as company reveals second quarter performance

- PMLiVE

AZ and BMS try again with Forxiga in the US

Pharma companies re-submit diabetes drug to the FDA for approval

China flag thumb

AstraZeneca and UCB drawn into Chinese investigations

Follows country’s clampdown on GSK bribery

- PMLiVE

Former AstraZeneca VP joins Walgreens

Mark Lelinski leaves pharma for pharmacy

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links